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ARTICLE OPEN
A data driven approach reveals disease similarity
on a molecular level
Kleanthi Lakiotaki 1*, George Georgakopoulos1, Elias Castanas 2, Oluf Dimitri Røe3,4,5, Giorgos Borboudakis1 and
Ioannis Tsamardinos 1,6,7*
Could there be unexpected similarities between different studies, diseases, or treatments, on a molecular level due to common
biological mechanisms involved? To answer this question, we develop a method for computing similarities between empirical,
statistical distributions of high-dimensional, low-sample datasets, and apply it on hundreds of -omics studies. The similarities lead to
dataset-to-dataset networks visualizing the landscape of a large portion of biological data. Potentially interesting similarities
connecting studies of different diseases are assembled in a disease-to-disease network. Exploring it, we discover numerous non-
trivial connections between Alzheimer’s disease and schizophrenia, asthma and psoriasis, or liver cancer and obesity, to name a
few. We then present a method that identifies the molecular quantities and pathways that contribute the most to the identified
similarities and could point to novel drug targets or provide biological insights. The proposed method acts as a “statistical
telescope” providing a global view of the constellation of biological data; readers can peek through it at: http://datascope.csd.uoc.
gr:25000/.
npj Systems Biology and Applications            (2019) 5:39 ; https://doi.org/10.1038/s41540-019-0117-0
INTRODUCTION
Public biological data repositories currently hold tens of thou-
sands of (bio)-datasets. For example, as of October 2019, the NCBI
Gene Expression Omnibus (GEO)1 contains 3,263,365 microarray
and RNA-Seq profiles, grouped into 119,386 data series. Each
dataset studies a specific biological question, regarding a disease,
a treatment, or a phenotype. Examples include finding the gene
expression differences between malignant and benign breast
tissue or creating a diagnostic model between primary and
metastatic lung cancer tumors. Data analysis methods then
typically focus on individually analyzing each dataset, like a
“statistical microscope”. However, the question arises: how do the
measurements from these studies compare against each other,
what are their relations, and what is the collective, emerging
picture and biological intuition they provide? Can we construct
and look through a “statistical telescope” instead? Could it be that
different diseases, treatments, other experimental or sampling
conditions induce similar biological molecular patterns pointing to
common pathophysiological pathways? Their identification could
accelerate the deeper understanding of human pathology and the
exploitation of clinical study results.
To address these questions, we compute similarities between
datasets, as distances between two empirical, multivariable,
statistical distributions (see Fig. 1).
A distributional similarity, referred simply as “similarity” here-
after, implies intuitively that molecular quantities measured in the
two datasets are inter-correlated in a similar way, i.e., the
covariance matrices are similar. We propose a generally applicable
method, able to robustly estimate distributional distances, even
when the dimensionality ranges into hundreds of thousands of
observed molecular quantities (variables, features, attributes) and
sample sizes as low as 40. It is emphasized that we compute the
similarity of two datasets based only upon the statistical proper-
ties of the molecular measurements and ignoring any textual
information. Similarities may arise due to several factors, such as
concerning the same disease or treatment, measuring the same
type of tissue, or employing sample analysis protocols and
equipment that induce similar systematic batch effects; similarities
may even arise between studies that share the same molecular
profiles, a phenomenon that is surprisingly prevalent2 (networks
depicting an alarming number of biological studies sharing
molecular profiles can be visualized interactively at http://
dataome.mensxmachina.org/networks). To account for shared
profiles, in this work, we remove all datasets with at least one
shared profile. However, when the method was applied,
unexpected similarities between studies of different tissue or
related to different pathologies were discovered, possibly
attributed to a common etiology in their underlying biology. To
enable expert inspection, we arranged the similarities into dataset-
to-dataset networks, one for each measuring platform, where
edges connect statistically significantly similar studies. The
networks visualize the landscape of a sizable portion of the
biological dataome and can be interactively explored online. To
focus attention on the potentially most interesting similarities, we
assemble the ones relating studies pertaining to different
pathologies or phenotypes into a new type of network: a
disease-to-disease network. Once an interesting dataset similarity
is identified, it is natural to inquire the reason why. A second
method is proposed to identify the molecular quantities (e.g.,
gene expressions) and corresponding enriched pathways, which
contribute the most to the identified similarity, thus providing
biological intuition regarding the common biological mechanisms
involved. The overall approach is depicted in Fig. 2.
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RESULTS
Visualizing the landscape of large portions of the Biological
Dataome
We used all the datasets from six measurement platforms that
comply with certain criteria for sample size; datasets that share
profiles with other datasets have been removed from considera-
tion (SM1.1). Datasets include both micro-array technologies on
transcriptomes and DNA methylomes, as well as RNA-seq
technology; they also include measurements on subject tissues
and cell lines. Specifically, the following platforms were included:
(1) Homo Sapiens, gene expression, Affymetrix Human Genome
U133 Plus 2.0 Array - (GPL570), (2) Homo Sapiens, gene expression,
Affymetrix Human Genome U133A Array - (GPL96), (3) Homo
Sapiens, gene expression, Affymetrix Human Gene 1.0 ST Array -
(GPL6244), (4) Homo Sapiens, gene expression, Illumina HiSeq
2000 - (GPL11154), Homo Sapiens, DNA methylation, Illumina
HumanMethylation450 BeadChip - (GPL13534), and Mus Musculus,
gene expression, Affymetrix Mouse Genome 430 2.0 Array -
(GPL1261). Overall 103,088 Homo Sapiens and Mus Musculus
samples were employed in the subsequent analyses and results,
grouped in 978 datasets and spanning more than 500 different
diseases and phenotypes, as revealed by automated text analysis.2
Their descriptive presentation is shown in Supplementary Figs 1
and 2.
For each pair of datasets within the same platform, we
computed the c-SKL as described in methods. The results are
visualized as networks (graphs), where each node corresponds to
a dataset (study) and each edge corresponds to a statistically
significant c-SKL. As only datasets within the same platform can be
compared, i.e., datasets measuring the same sets of variables, a
different network is constructed for each platform. The network
for GPL570 and all statistically significant edges is shown in Fig. 3a;
the networks for the other platforms are found in SM5. Figure 3b
depicts the same network, when only the top 300 most
statistically significant edges are included. In the figure, several
communities emerge (a community is defined as a set of nodes
densely interconnected). Manually inspecting and annotating the
nodes provides evidence for the efficacy of the method: in Fig. 3b,
we observe that datasets within a community typically pertain to
the same disease and/or tissue, which could explain the
similarities found. Missing edges are potentially interesting and
informative too: the GSE20036 dataset was one of the few that
had no edge to any other dataset for the GPL570 platform and is
thus not shown in the network. On closer inspection, the dataset
refers to gene expression analysis of deer antler measured using
human micro-arrays which explains a high c-SKL with all the other
human datasets. There are two communities of breast cancer
shown that are not connected; on closer inspection the largest
one contains case-control studies on human subjects, while the
other contains treatment-control studies on cell lines, justifying
why the c-SKL is high among studies belonging in these two
different groups. It is well known that significant differences
between cell lines and human tumors exist.3
It is also interesting to study the evolution of these networks,
e.g., using the on-line app provided, as one varies the number of
edges to include. In general, as we increase the number of edges
in the network, similar communities tend to connect and merge
together. For example, if we go beyond the 300 edges shown in
Fig. 3b, we will observe the brain diseases’ community merging
with the glioma community and the several lymphoma related
datasets to connect with each other. Some more snapshots of the
Low SKL->High similarity
A B
C
Fig. 1 Comparing empirical, high-dimensional statistical distributions. A visual example of pairwise comparison of three, standardized,
bivariate normal distributions. Each point corresponds to a molecular profile measuring just two quantities. Contours are drawn to indicate
regions of equal probability density. The comparison is generally based on the covariance matrix. In this case, what matters is the single
covariance between the two quantities measured: positive for datasets A and B, and negative for C. Distribution of A is more similar to B than
to C. In high-dimensional spaces, the contours become surfaces that form ellipsoids. Geometrically, the distributions are compared based on
size and orientation of these ellipsoids. The metric of (dis)similarity proposed approximates the Symmetric Kullback–Leibler divergence and is
denoted as c-SKL
K. Lakiotaki et al.
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Fig. 2 Towards a landscape of the biological dataome. a Problem definition: identify statistical similarities on a molecular level among public
-omics datasets. b Compute all pairwise similarities based on the curated Symmetric Kullback–Leibler (c-SKL) divergence and the similarity of
the covariance matrices. c The network of similarities among datasets of the same platform is visualized and explored for novel biological
findings. The dataset similarity networks lead to a disease similarity network. d To gain intuition on the molecular underpinnings of interesting
similarities, the molecular quantities that influence the c-SKL metric the most, are reported; these correspond to the same rows and columns
in the covariance matrices not grayed out in the matrices on the right. They are used further as input for (pathway, gene ontology) enrichment
analysis
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networks for different number of edges and platforms are shown
in SM5.
From dataset similarity to disease similarity
Even though the proposed c-SKL metric cannot distinguish among
the sources of observed similarities, yet, it can point-out
unexpected similarities. For example, the similarity networks (SM
5) demonstrate that tissue is not the only reason of similarity, as
we notice significant similarities in datasets measuring different
tissues (i.e., anterior orbit or lacrimal gland and blood). At the
same time, not all datasets providing data from the same tissue
interconnect, e.g., datasets of blood tissue measurements do not
fully interconnect. To systematically extricate non-trivial and
potentially interesting similarities, we focused on the similarities
that connect macroscopically different diseases. We construct a
new type of network where each node corresponds to a different
disease, or phenotype in a more general sense, a disease-to-
disease network: two nodes A and B in this network are connected
by an edge (A,B), whenever a dataset of disease A is found similar
to a dataset of disease B. We construct one disease-to-disease
network for each different species (Homo Sapiens and Mus
Musculus) and each type of -omics (transcriptomics and methy-
lomics) by assembling all edges from all related platforms. Figure 4
shows the disease-to-disease network for Homo Sapiens tran-
scriptomics (both micro-array and RNA-seq based), Homo Sapiens
methylomics as formed by similarities based on DNA methylation
levels of >450,000 CpG methylation sites and Mus Musculus
transcriptomics. The networks depict disease similarities at the
molecular level. The methylomics disease network is much
smaller, as there are only 117 datasets from the GPL13534
platform. Edges (A, B) in Fig. 4 are annotated with a weight,
corresponding to edge thickness, equal to the number of times a
pair of studies one from disease A and one from B are found
similar. Thus, edges of high weight indicate a molecular similarity
between different diseases found multiple times across studies
and platforms and that could be attributed to an underlying
common biological mechanism. Figure 4 (top) for human
transcriptomics shows only the edges of weight 3 and above,
while Fig. 4 (bottom right) for methylomics shows edges of weight
2 and above, as methylation datasets are much fewer and edge
weights are lower. Figure 4 (bottom left) shows Mus Musculus
transcriptomics from the GPL1261 platform.
Focusing on Fig. 4 (top), the strongest edge with weight of 34 is
found between breast cancer and lung cancer. The finding
provides additional evidence to the literature: it has been recently
reported that lung tumors express estrogen receptor alpha, which
is a common trait in >70% of breast tumors, and whose activation
expresses pathways related to cell proliferation and metastasis,4
common elements shared with pathways identified in breast
cancer.5 Also, a connection between breast cancer and thyroid
cancer appears (weight= 7), a relationship that has attracted
substantial attention in the medical research community.6
Alzheimer’s disease and schizophrenia, a similarity found in eight
different data-pairs, is known to share psychiatric symptoms that
suggest some common cerebral pathophysiology.7 In,8 a network
that spatially recapitulates the pattern of brain abnormalities
observed in both schizophrenia and Alzheimer’s disease was
revealed by a data driven analysis. Psoriasis and asthma (weight=
6), both chronic immune-mediated inflammatory diseases, is
another example of a rather unexpected similarity, which has
attracted much attention recently.9 Melanoma and breast cancer,
an already known similarity10–12 also appears frequently (weight=
5). Other interesting, frequent similarities that can be further
supported by evidence found in the literature, include the links
between acute myeloid leukemia and viral infectious diseases
(weight= 7),13 asthma and malaria (weight= 5),14 asthma and
hepatitis C (weight= 6),15 systemic lupus erythematosus and viral
infectious disease (weight= 6),16 or Parkinson’s disease and
Alzheimer’s disease (weight= 2, out of the only two available
Parkinson’s disease datasets).17 It is also interesting to note that in
the Mus Musculus transcriptome network the most frequent
Fig. 3 Dataset-to-dataset network of Homo Sapiens datasets measured by GPL570. a A telescopic view of all datasets measured by GPL570
(excluding studies with shared molecular profiles) including all of 1562 statistically significant edges. b The top 300 most statistically
significant edges of the same network. Manual inspection and annotation, corresponding to the colored areas, show that nodes within
communities (densely interconnected network regions) typically pertain to the same disease or tissue, which could explain the identified
molecular similarities and provides biological evidence of the efficacy of the method
K. Lakiotaki et al.
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Fig. 4 Disease networks of Homo Sapiens and Mus Musculus. Nodes represent diseases or phenotypes (i.e., response to exercise). Edge
weights (denoted with the edge thickness) represent the number of times (number of dataset pairs) the corresponding disease-disease
relation has been found. Node size increases with the number of neighbors
K. Lakiotaki et al.
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Fig. 5 Statistically and biologically explaining a high-dimensional curated Symmetric Kullback–Leibler Divergence. a c-SKL versus the number
of top k probe sets that best explain the similarity of two datasets (GSE37171 and GSE46474 measured by GPL570) is shown in red. Gray color
corresponds to the c-SKL computed using the same number of randomly selected probe sets. b Jaccard similarity coefficient between two
cliques of AML measured by different platforms, GPL570 (microarray) and GPL11154 (RNA-seq) is shown in red. Gray color corresponds to the
Jaccard index of the same similarity computed based on a random selection of genes. c, d Enrichment maps of the 20 most statistically
significantly enriched pathways by the genes that explain a breast cancer clique of ten datasets measured by GPL570 and the similarity of
eight different pairs of datasets connecting Alzheimer’s disease with schizophrenia
K. Lakiotaki et al.
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similarity was found between obesity and liver cancer (weight=
6). See ref. 18 for a review on the existing evidence on the links
between obesity and liver cancer incidence and survival and19 for
a pooled analysis from all U.S. based studies in the NCI Cohort
Consortium. For a ranked list of all disease associations that have
been found at least four times in any of the Homo Sapiens
platforms see Table 2 in SM6.
Uncovering molecular underpinnings of statistical similarities
Once an interesting similarity in the dataset-to-dataset network
has been identified, it becomes important to explain it in a way
that conveys biological insight and understanding. The above
methods and ideas are exemplified in Fig. 5. Specifically, we
consider the similarity between datasets GSE37171 and GSE46474
measured by GPL570. This is the most statistically significant
similarity found in any pair of datasets examined. In Fig. 5a we
show that the c-SKL achieved using the B(k) features (shown in
red), obtained by the proposed optimization method that explains
c-SKL (see Methods), dominates (obtains a lower c-SKL) the c-SKL
achieved by randomly selecting k features (gray color). The graph
starts at value k= 100 with a step size of 1000. More examples are
shown in SM4.1, demonstrating that the curves are qualitatively
similar over the whole range of similarities and platforms. The
results clearly show that B(k) selects better explaining features
than random guessing. Next, we consider the hypothesis that, for
the same disease, the biological mechanisms that best explain
similarities between datasets at the transcriptome level, should be
common, independently of the measuring technology. As an
example, we first identified an acute myeloid leukemia (AML)
clique of five datasets measured by GPL570 (microarray gene-
expression) and an AML clique of five datasets measured by
GPL11154 (RNA-seq) and compared the gene sets that explain
their similarity (see Fig. 5b). The Jaccard index when including all
~50000 probe sets measured by both platforms is 0.62. This
number is closely approximated when the number of best
explaining probe sets is 15,000–20,000. The gray dots correspond
to the Jaccard index of random selection of probe sets between
the two platforms for comparison. A qualitatively similar plot for
another example on psoriasis can be found in SM8. These two
examples illustrate that the lists of genes explaining the
similarities among datasets of the same disease are similar across
measuring platforms.
Finally, we show two examples of the ability of the method to
convey biological intuition in the form of a set explanation.
Specifically, we simultaneously explain using 1000 probe-sets, (a)
all 45 pair-wise similarities found within a clique of ten breast-
cancer datasets and (b) eight similarities of Alzheimer’s disease to
schizophrenia. In both cases, the datasets are gene-expression
micro-arrays measured by GPL570. The probe-sets are then
mapped to their corresponding gene symbols and an enrichment
analysis of KEGG pathways is performed. Figure 5c, d visualizes the
enriched pathways as enrichment maps. Regarding (a), the map
(Fig. 5c) for explaining the breast cancer clique shows several
immune related pathways that verify the already known immune
system tumor infiltration related to breast cancer evolution (see
SM7 for a detailed discussion). A similar example and discussion
on a lung cancer clique is shown in SM7. Regarding (b), the
pathways (Fig. 5d) that explain the similarity of Alzheimer’s
disease to schizophrenia include six out of the ten KEGG pathways
that are related to the nervous system.
DISCUSSION
The traditional disease classification system (e.g., ICD20) groups
diseases with similar clinical symptoms and phenotypic traits. One
of the first attempts to group diseaes with common genetic origin
was the work by Goh et al.,21 who created the Diseasome, a visual
reference of the genetic links between disorders and disease
genes. The human disease network they created, displayed many
connections between both individual disorders and disorder
classes and proved that studying diseases and phenotypes from a
systems approach offers the possibility to discover general
patterns and principles of human disease. Since then, several
network based approaches to understand the molecular basis of
human disease, appeared. Hidalgo et al.,22 for example, exploited
disease phenotypes of more than 30 million elderly Americans
aged 65 or older, to create a Phenotypic Disease Network (PDN)
where nodes represented disease phenotypes, as defined by the
ICD9 and edges a significant comorbidity according to the
measures they introduced. Later, Žitnik et al.23 found relationships
between diseases, some of them undiscovered at that time, by
fusing molecular interaction and ontology data from several
biological databases, such as Gene Ontology, Disease Ontology,
DrugBank and others. Sun et al.24 estimated the similarity score of
diseases, by analyzing four publicly available disease-gene
association datasets (OMIM, CTD, FunDO, and HuGENet) and
demonstrated their similarity measure by identifying diseases
associated with diabetes mellitus which were further confirmed
bibliographically. Yang et al.25 proposed a more data driven
approach, by applying differential co-expression analysis to
explore the architecture of disease relationships in terms of
dysfunctional regulation mechanism. Their results proved that
their approach can be a complement to the disease networks
generated from symptoms, disease concepts and biomedical data.
Later, Menche et al.26 identified common mechanistic pathways
between diseases by exploiting the overlap of disease modules
(connected subgraphs formed by the interaction of disease
proteins). Recently, Halu et al.27 developed and analyzed the
human disease multiplex network by considering genotypic and
phenotypic information simultaneously and showed, among other
results, that Mendelian disorders predispose individuals to more
common, complex diseases. Other approaches that compare
biological datasets rely on creating a molecular signature list for
each dataset containing the differentially expressed quantities
with respect to a target variable (supervised approach). A typical
such target variable in case-control studies is the disease status,
and in treatment-control studies it is the presence or absence of
treatment. Dataset similarities are then computed as similarities
between the signature lists.28–30
The above studies do not take advantage of the enormous and
rapidly growing public repositories of omics data or may require
phenotypic annotation and labeling of samples and datasets
(supervised approaches). The latter is technically difficult to
perform automatically and scale up to thousands of datasets.
Instead, in this work, we propose a method that is unsupervised
and depends only on the omics data distributions. Hence, it can
easily be applied to the entire collection of available omics
datasets.
The proposed method could also be employed for what we call
data-based information retrieval, i.e., retrieving all datasets that are
similar to a particular query dataset (e.g., return all public mice
datasets with molecular patterns similar to a users’ mice profiles
under a specific new treatment). Data with similar statistical
properties as the query data could be potentially pooled together
for meta-analysis or identify similar control samples from totally
unrelated studies. It is worthwhile to note that quite recently,
Google launched a new service, called Dataset Search, also aiming
at dataset retrieval. However, Dataset Search performs retrieval
based on the metadata tags, while the proposed method
identifies statistically similar datasets independently of any text
or tag annotations.
As most human public -omics datasets are case-control studies,
in this work we focused on disease-to-disease similarities;
however, in the context of drug design, one could examine
treatment-control studies to create treatment-to-treatment
K. Lakiotaki et al.
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networks depicting similarities between expression patterns
induced by different compounds. Compounds, tested for different
diseases that yet induce similar expression patters for unexpected
reasons, are prime candidates for drug repurposing.
If one annotates datasets with the tissue measured (or some
other datasets characteristic), then it is possible to estimate the
principal component corresponding to the tissue and remove it.
Recomputing similarities after this removal will highlight simila-
rities due to all other reasons except tissue, further revealing
common biological mechanisms among different diseases.
Finally, while the proposed method requires two datasets to be
measuring the same set of variables (molecular quantities), it is
possible to develop methods of comparing distributions over
different sets of variables (human genes vs. mice genes), an
interesting line of future work that we are actively exploring.
METHODS
Comparing statistical distributions of high-dimensional, low-
sample datasets
Two datasets can be viewed as two dimensional matrices DSP and DSQ with
rows ranging over the samples and columns over the variables (features,
molecular quantities measured, attributes; e.g., in the context of gene-
expression micro-arrays variables are probe sets). For -omics data, such as
micro-array or RNA-seq data, the number of variables ranges into the tens
to hundreds of thousands, while often the sample size is less than a few
dozens. To compare such high dimensional, low-sample size empirical
distributions, we propose the following methodology: First, each dataset is
standardized by subtracting the mean and dividing by the standard
deviation of a variable for each measured value. Standardization removes
the effect of the mean and the scale of the measurements, which could
depend on the sensitivity of the measuring instrument and the
concentration of the reagents and may be sensitive to other nuisance
factors. This transformation retains the linear correlations among variables.
Second, each dataset DSP’s distribution is assumed to be multivariate
normal and thus fully determined by its mean (which is transformed to
zero) and its symmetric, positive semidefinite covariance matrix ΣP
(coinciding with the correlation matrix for standardized data). Given that
the number of variables is larger than the number of samples, the sample
covariance matrix is rank deficient. A third assumption (which enables the
estimation of the rank-deficient covariance matrix) is that ΣP can be
expressed as ΣP= PΛ
PPT+ σPI, where Pn×k is an orthonormal matrix, Λ
P
k×k a
diagonal matrix with the ith value in the diagonal denoted as λ
P
i  0, and
σP a non-negative real. In other words, it is assumed that the data lie in a k
<< n dimensional subspace, where n is the number of variables, with an
isotropic noise component (see SM2.1). The decomposition of ΣP is
computed using the standard Principal Component Analysis. Alternatively,
one could employ Probabilistic PCA to directly compute the maximum
likelihood decomposition of ΣP
31 at the expense of higher computational
cost. P is the matrix of the first k= cP principal axes of the sample
covariance matrix, λPi the corresponding eigenvalues (
ffiffiffiffi
λPi
q
are the singular
values of DSP). Similarly, for dataset DSQ we compute the decomposition
ΣQ = QΛ
QQT + σQI, where Q is the matrix of the first cQ principal axes
and ΛQ contains the cQ eigenvalues of the covariance matrix in its diagonal.
Based on the above ideas, we develop a measure of (dis)similarity between
the distributions of the two datasets DSP and DSQ, called the curated
symmetric Kullback–Leibler (c-SKL) divergence, and denoted as c-SKL (ΣP,
ΣQ). This measure depends only on the covariance matrices given the
above assumptions. The smaller the c-SKL between a pair of datasets, the
more similar the two distributions and their covariance matrices are (Fig.
2b). c-SKL is symmetric and non-negative, but the triangle inequality does
not necessarily hold, so it is not a proper metric.32 Other similarity metrics
for high-dimensional, low-sample settings could be employed, such as the
Maximum Mean Discrepancy or MMD.33 However, the proposed c-SKL
depends on a PCA decomposition that can be explainable, as we later
demonstrate; in addition, the PCA decomposition can be pre-computed
and stored for each dataset to be employed for all subsequent pairwise c-
SKL computations. This type of caching makes c-SKL computations efficient
for applications when the collection of datasets is constantly updated.
Based on the assumptions above, for two datasets DSP and DSQ, where σ ≈
σP ≈ σQ the c-SKL can be approximated as:
c  SKL ah i ΣP;ΣQð Þ  12ð1 aÞ 2an
XcP
i¼1
XcQ
j¼1
λPi P
T
i  Qj
 2
XcP
i¼1
XcQ
j¼1
λQi P
T
i  Qj
 2
" #
(1)
Equation (1) is an approximate version of Eq. 26 shown in SM 2.2. Both
equations are proved in SM 2.2. Equation (1) has an intuitive geometric
interpretation: the first double sum computes the squared length of the
projections of
ffiffiffiffi
λPi
q
Pi onto the subspace spanned by the principal axes of Q.
The reverse is true for the second double sum. Obviously, the c-SKL
divergence is minimized when the two subspaces coincide. The empirical
success of the formula depends on the choices of the number of principal
axes to retain cP and the value of σP in each decomposition
ΣP ¼ PΛPPT þ σPI. Selecting the first cP principal axes to retain explainsPcP
i¼1 λ
P
i of the total dataset variance n (since there are n variables, each with
variance and standard deviation of 1). The value of cP is determined in such a
way that the first term explains just about αP percent of the variance, i.e.,
cp ¼ argmin c2Nf g
Pc
i¼1 λ
P
i  αPn
 
. The parameter αP dictates the level of
compression of the data. As αP increases, more principal axes are employed,
enlarging the axes subspace and allowing finer differences (dissimilarities) to
other datasets to be discovered; at the same time, as αP increases the
additional axes entering the equation are less reliably estimated. The
parameter αP is the variance-per-variable unexplained by the principal
components and distributed to the isotropic noise components. We set it to
1− αP so that the sum of variances in the decomposition equals the variance
of the original dataset. Employing the same value for αP in all c-SKL
computations among different pairs of datasets (leading to drop the index P
from the notation), makes two c-SKL values comparable as they are all
computed using the same compression level. In fact, after experimentation
we found that results improve when eigenvalues are scaled so that they sum
exactly to α, i.e,
PcP
i¼1 λ̂
P
i ¼ α, where λ̂ are the normalized values (the method
is graphically depicted and explained in SM section 2.3–2.4 and Supplemen-
tary Fig. 3). In order to statistically validate the method, we performed the
following computational experiment: We randomly partitioned each dataset,
with respect to samples, into two “sibling” datasets DS1 and DS2. We
computed c-SKL among each pair of all available datasets, agnostic to the
above partitioning. By construction, the sibling datasets come from the same
distribution and should be discovered to be closer in c-SKL than with any
other dataset. The validation experiment and its results are presented in
detail in SM3, where we show that the sibling of a dataset is found closer in
terms of c-SKL than any other dataset 95% of times. From the experiment we
also determined a reasonable value for α to be 50%, but results are robust
with respect to the specific numerical value used. We then estimate the
statistical significance of similarities and keep only the ones with a q-value
(adjusted p-value for multiple testing based on the Benjamini and Hochberg
procedure34) less than 0.05 using a semi-parametric bootstrap technique. The
semi-parametric bootstrap testing procedure is as follows: Let J be the
distribution of the pooled samples across all datasets; let P and Q be the
distributions of two datasets DSP and DSQ. The alternative hypothesis tested
is that the observed c-SKLs between P and Q is smaller (and thus their
similarity is larger) than the c-SKLs of P and J, as well as Q and J. In other
words, a statistically significant similarity indicates that two datasets are more
similar to each other, than with the rest of the samples (see also SM 2.4). We
note that, there exist procedures in the literature testing the exact equality of
high-dimensional distributions,33,35 i.e., H0: P=Q or equivalently, H0: s= 0,
where s is their c-SKL. However, in the context of this work, the null
hypothesis of exact equality of distributions is meaningless and should
typically be rejected; studies may be related, but do not necessarily employ
exactly the same population under the same experimental and sampling
conditions. Instead, we propose to test for a relatively high similarity with
respect to the rest of the samples in the pooled collection of all datasets.
Explaining a curated Symmetric Kullback–Leibler Divergence
It is not straightforward to explain why two distributions over tens of
thousands of dimensions are similar. As an explanation, we propose to
report the top k molecular quantities, to which the similarity can be mostly
attributed. As proved in SM2.2 (Lemma 2), a low Kullback–Leibler
divergence corresponds to a similarity between the corresponding
covariance matrices ΣP and ΣQ. The most contributing features correspond
to the rows and columns of the covariance matrices, where the matrices
agree the most (see Fig. 2d and SM section 2.5 for a discussion). The set of
best “explaining” features can then be examined for enrichment of
K. Lakiotaki et al.
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pathways, ontologies, or other predefined interesting groups of molecular
entities. To find the top k best explaining index set B (for Best) given two
datasets with principal axes in P and Q, and eigenvalues in vectors λP and
λQ one needs to solve the following optimization problem:
B kð Þ ¼ argminS
1
2 1 að Þ 2an
XcP
i¼1
XcQ
j¼1
λPi þ λQj
 
PTi diag Sð ÞQj
 2
" #
; (2)
such that S is a vector of exactly k ones and everything else zero, and diag
(S) produces a diagonal matrix with S on the diagonal. The S vector serves
as the selector of features in the computation of Eq. (1). The parameter k is
arbitrarily selected by the user. This is a quadratic, constrained optimiza-
tion problem that can efficiently be solved approximately by considering
its bilinear form:
argmaxT ;S
XcP
i¼1
XcQ
j¼1
Cij P
T
i diag Tð ÞQj
 
PTi diag Sð ÞQj
 " #
: (3)
where Cij ¼ ðλPi þ λQj Þ. A simple algorithm for solving (3) starts with an
initial value for S and alternating between solving for vectors T and S until
convergence when T= S= B. Solving for T considering S fixed and vice-
versa is a linear, constrained problem that can be solved trivially (see SM
section 2.5 for more details). In addition to identifying the indexes of the k
best-explaining features B(k), one can instead minimize the equation
above to find the top k features that make the distributions most different,
denoted by W(k) (standing for Worst).
As presented, B(k) explains a single dataset-to-dataset similarity; however,
one could extend this method to find the features that simultaneously best
explain a set of pair-wise dataset similarities, trying to pick the common
biological mechanisms that are jointly responsible for all similarities observed
in the set. To find the best set explanation among a set of pair-wise
similarities, we solve a similar optimization problem maximizing the sum of
all pair-wise c-SKLs within the set (see SM2.5 for an efficient implementation
of this algorithm). There are at least two scenarios where a set explanation
could be useful. For example, one may wish to explain all pair-wise
similarities among datasets pertaining to the same disease. These datasets
may differ slightly in terms of patient population, experimental conditions,
and sampling methodology; identifying the genes that explain the patterns
shared by all of them, accentuates the common cause for the similarities in
the group, presumably those genes involved in the common disease
mechanism. A second use of a set explanation is when trying to explain an
edge in the disease-to-disease network. Each such edge corresponds to a set
of similarities whose set explanation sheds light to the common mechanism
involved in making the two different diseases similar.
Reporting summary
Further information on research design is available in the Nature Research
Reporting Summary linked to this article.
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